Renal Sympathetic Denervation by CT-scan-Guided Periarterial Ethanol Injection in Sheep

CardioVascular and Interventional Radiology

Volumn 38, Issue 4, 2015, Pages 977-984

  Firouznia, Kavous ^a,b   Hosseininasab, Sayed jaber ^a,b   Amanpour, Saeid ^c   Haj Mirzaian, Arya ^b   Miri, Roza ^b   Muhammadnejad, Ahad ^c   Muhammadnejad, Samad ^d   Jalali, Amir H ^a,b   Ahmadi, Farrokhlagha ^b   Rokni Yazdi, Hadi ^a,b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

CT scan guided ethanol injection; Hypertension; Renal sympathetic denervation; Sheep

Indexed keywords

ALCOHOL; CREATININE; IOHEXOL; LIDOCAINE; NORADRENALIN; THIOPENTAL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; INJECTION; KIDNEY ARTERY; KIDNEY DENERVATION; KIDNEY PARENCHYMA; MAGNETIC RESONANCE ANGIOGRAPHY; NONHUMAN; NORADRENALIN BLOOD LEVEL; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; SHEEP; UROGRAPHY; ANIMAL; FEASIBILITY STUDY; INNERVATION; INTERVENTIONAL RADIOLOGY; KIDNEY; PROCEDURES; RADIOGRAPHY; SYMPATHECTOMY;

ANIMALS; ETHANOL; FEASIBILITY STUDIES; KIDNEY; MODELS, ANIMAL; RADIOGRAPHY, INTERVENTIONAL; RENAL ARTERY; SHEEP; SYMPATHECTOMY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84937519335     PISSN: 01741551     EISSN: 1432086X     Source Type: Journal    
DOI: 10.1007/s00270-015-1109-0     Document Type: Article

References (39)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217–23.
2. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–13.
3. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart disease and stroke statistics—2010 update A report from the American Heart Association. Circulation. 2010;121(7):e46–215.
4. Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA. 2005;294(4):466–72.
5. Ostchega Y, Yoon SS, Hughes J, Louis T. Hypertension awareness, treatment, and control–continued disparities in adults: United States, 2005-2006. NCHS data brief. 2008;3:1–8.
6. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA. 2010;303(20):2043–50.
7. Esler M, Jennings G, Korner P, Blombery P, Burke F, Willett I, et al. Total, and organ-specific, noradrenaline plasma kinetics in essential hypertension. Clin Exp Hypertens A. 1984;6(1–2):507–21.
8. Veith RC, Lewis N, Linares OA, Barnes RF, Raskind MA, Villacres EC, et al. Sympathetic nervous system activity in major depression: basal and desipramine-induced alterations in plasma norepinephrine kinetics. Arch Gen Psychiatry. 1994;51(5):411–22.
9. Esler MD, Krum H, Schlaich M, Schmieder RE, Böhm M, Sobotka PA. Renal sympathetic denervation for treatment of drug-resistant hypertension one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation. 2012;126(25):2976–82.
10. Ahmed H, Neuzil P, Skoda J, Petru J, Sediva L, Schejbalova M, et al. Renal sympathetic denervation using an irrigated radiofrequency ablation catheter for the management of drug-resistant hypertension. JACC Cardiovasc Interv. 2012;5(7):758–65.
11. Mahfoud F, Cremers B, Janker J, Link B, Vonend O, Ukena C, et al. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension. 2012;60(2):419–24.
12. Rippy MK, Zarins D, Barman NC, Wu A, Duncan KL, Zarins CK. Catheter-based renal sympathetic denervation: chronic preclinical evidence for renal artery safety. Clin Res Cardiol. 2011;100(12):1095–101.
13. Vonend O, Antoch G, Rump LC, Blondin D. Secondary rise in blood pressure after renal denervation. Lancet. 2012;380(9843):778.
14. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275–81.
15. Kandzari DE, Bhatt DL, Sobotka PA, O’Neill WW, Esler M, Flack JM, et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol. 2012;35(9):528–35.
16. Okada T, Pellerin O, Savard S, Curis E, Monge M, Frank M, et al. Eligibility for Renal Denervation: Anatomical Classification and Results in Essential Resistant Hypertension. Cardiovasc Intervent Radiol. 2015;38(1):79–87.
17. Streitparth F, Walter A, Stolzenburg N, Heckmann L, Breinl J, Rinnenthal J, et al. MR-guided periarterial ethanol injection for renal sympathetic denervation: a feasibility study in pigs. Cardiovasc Intervent Radiol. 2013;36(3):791–6.
18. Schmid MR, Kissling RO, Curt A, Jaschko G, Hodler J. Sympathetic Skin Response: monitoring of CT-guided Lumbar Sympathetic Blocks 1. Radiology. 2006;241(2):595–602.
19. Lee M, Mueller P, VanSonnenberg E, Dawson S, D’Agostino H, Saini S, et al. CT-guided celiac ganglion block with alcohol. AJR Am J Roentgenol. 1993;161(3):633–6.
20. Bahn BM, Erdek MA. Celiac plexus block and neurolysis for pancreatic cancer. Curr Pain Headache Rep. 2013;17(2):310.
21. Watarida S, Shiraishi S, Fujimura M, Hirano M, Nishi T, Imura M, et al. Laparoscopic lumbar sympathectomy for lower-limb disease. Surg Endosc. 2002;16(3):500–3.
22. Matsumoto Y, Ueyama T, Endo M, Sasaki H, Kasashima F, Abe Y, et al. Endoscopic thoracic sympathicotomy for Raynaud’s phenomenon. J Vasc Surg. 2002;36(1):57–61.
23. Kim WO, Yoon KB, Kil HK, Yoon DM. Chemical lumbar sympathetic block in the treatment of plantar hyperhidrosis: a study of 69 patients. Dermatol Surg. 2008;34(10):1340–5.
24. Streitparth F, Gebauer B, Nickel P, Reinke P, Freyhardt P, Wieners G, et al. Percutaneous Computer Tomography-Guided Ethanol Sympathicolysis for the Treatment of Resistant Arterial Hypertension. Cardiovasc Intervent Radiol. 2014;37(2):513–8.
25. Sakakura K, Ladich E, Edelman ER, Markham P, Stanley JRL, Keating J, et al. Methodological Standardization for the Pre-Clinical Evaluation of Renal Sympathetic Denervation. JACC Cardiovasc Interv. 2014;7(10):1184–93.
26. Bauch H, Kelsch U, Hauss W. A single, rapid, selective and quantitative determination of adrenaline and noradrenaline in the plasma by a combination of solvent extraction, HPLC separation and electrochemical detection. J Clin Chem Clin Biochem. 1986;24(9):651–8.
27. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Mancia G. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension. 1998;31(1):68–72.
28. Esler M, Lambert G, Jennings G. Regional norepinephrine turnover in human hypertension. Clin Exp Hypertens A. 1989;11(Suppl 1):75–89.
29. Zanchetti AS. Neural regulation of renin release: experimental evidence and clinical implications in arterial hypertension. Circulation. 1977;56(5):691–8.
30. Bell-Reuss E, Trevino D, Gottschalk C. Effect of renal sympathetic nerve stimulation on proximal water and sodium reabsorption. J Clin Invest. 1976;57(4):1104–7.
31. Kirchheim H, Ehmke H, Persson P. Sympathetic modulation of renal hemodynamics, renin release and sodium excretion. Klin Wochenschr. 1989;67(17):858–64.
32. Kon V. Neural control of renal circulation. Miner Electrolyte Metab. 1989;15(1–2):33–43.
33. Investigators SH. Catheter-based renal sympathetic denervation for resistant hypertension durability of blood pressure reduction out to 24 months. Hypertension. 2011;57(5):911–7.
34. Esler M, Krum H, Sobotka P, Schlaich M, Schmieder R, Böhm M. Symplicity HTN-2 Investigators Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Circulation. 2012;126(25):2976–82.
35. Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet. 2015. doi:10.1016/S0140-6736(14)61942-5.
36. Worthley SG, Tsioufis CP, Worthley MI, Sinhal A, Chew DP, Meredith IT, et al. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J. 2013;34(28):2132–40.
37. Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393–401.
38. Fischell TA, Vega F, Raju N, Johnson ET, Kent DJ, Ragland RR, et al. Ethanol-mediated perivascular renal sympathetic denervation: preclinical validation of safety and efficacy in a porcine model. EuroIntervention. 2013;9(1):140–7.
39. Esler M, Schlaich M, Sobotka P, et al. Catheter-based renal denervation reduces total body and renal noradrenaline spillover and blood pressure in resistant hypertension. J Hypertens. 2009;27(suppl 4):s167.